Andrew Cowan

Oct 22, 2024 | mondaq.com | Andrew Cowan |Gemma Bell

This recent investigation related to a complaint made around the way in which the Global Warming Policy Foundation (the "Foundation") operated. One element of the complaint concerned the relationship between the Foundation, which is a registered charity, and its trading company subsidiary, the Global Warming Policy Forum.

Oct 18, 2024 | housingtoday.co.uk | Andrew Cowan |Samantha Grix

Why convergence needs to be a part of any new social housing rent settlement By Andrew Cowan and Samantha Grix 2024-10-18T06:00:00 Rents in social housing are complicated and this must change over time, argues Andrew Cowan Sometimes, complexity is the price of doing business. But sometimes complexity comes as a result of changes in policy without rethinking the legacy systems which are already in place. The system for calculating social housing rents is a good example of the latter.

May 3, 2024 | gateleyplc.com | Andrew Cowan

Gateley Legal and the deals we have advised on have secured eight nominations at The Business Desk West Midlands Rainmakers Awards 2024. We are shortlisted for National Legal Team, associate Janai Parker is named in the Changemaker of the Year category and six of our deals are shortlisted across five categories including International Deal of the Year, Private Equity Exit of the Year, Large Deal of the Year (over £50m), Medium Deal of the Year (£10-50m) and Small Deal of the Year (up to £10m).

Nov 28, 2023 | onlinelibrary.wiley.com | Andrew Cowan |Damian Green

In their paper the authors ‘Genetic defects of gamma-secretase genes in a multiple myeloma patient with high and dysregulated B cell maturation antigen (BCMA) surface density: a case report’, propose a novel defect in gamma-secretase genes that results in high and dysregulated BCMA surface density in a multiple myeloma (MM) patient.1 They describe 20 MM patients who underwent characterization of BCMA surface levels on malignant plasma cells, followed by treatment with the gamma-secretase...

Nov 5, 2023 | nature.com | Rahul Banerjee |Andrew Cowan |S. Vincent Rajkumar

Dear Editor,The proteasome inhibitor bortezomib is a key component of treatment regimens for newly diagnosed multiple myeloma (MM). Bortezomib has been dosed twice per week in both industry-sponsored and consortium-run trials of MM induction regimens [1,2,3,4,5]. However, several analyses (Table 1) have demonstrated comparable efficacy with once-weekly versus twice-weekly bortezomib in MM [6,7,8,9].